IAI SPECIAL EDITION: Study of potential interactions of oral antidiabetic drugs in patients with type 2 diabetes mellitus with comorbidities: A retrospective study
DOI:
https://doi.org/10.46542/pe.2022.222.200206Keywords:
Diabetes mellitus, Drug interaction, Oral antidiabeticAbstract
Background: Diabetes mellitus (DM) has many complications, such as microvascular and macrovascular complications. Patients are given polypharmacy therapy to combat these issues, which can cause drug interactions. Oral antidiabetic drugs were chosen based on their risk profile. Risk assessment aided treatment intensity targeting. The number of drugs taken can increase the risk of drug interactions causing health issues.
Objective: To identify potential drug interactions based on their severity (major, moderate and minor) and the mechanism of the drug interaction (pharmacokinetics and pharmacodynamics), in type two diabetes mellitus patients with comorbidities at the Lamongan Health Center.
Methods: This was a cross-sectional study using medical records and patient prescriptions from October 2020 to June 2021 at Puskesmas (Primary Health Centers) Deket, Karanggeneng, and Babat. The data were descriptively analysed. Drug interactions were analysed using drugs.com and Stockley. Purposive sampling was used to select 194 patients for inclusion.
Results: From October 2020 to June 2021, 110 out of 194 outpatients at Lamongan Regional Health Center had potential drug interactions (56.7 %). The most common type of drug interaction was of moderate severity, with 120 cases (93.0%), and the most common mechanism was pharmacodynamics (61.2%).
Conclusion: Polypharmacy is a difficult problem to avoid, so drug therapy monitoring is required in diabetic patients to minimise unwanted effects. Preventing potential drug interactions requires a system for early detection of potential drug interactions that may occur in patient prescribing and maximising pharmaceutical care. This system would allow for the community to be more proactive in finding out about potential drug interactions.
References
Baxter, K. (2010). Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance and management. Choice Reviews Online, 48(03), 48-1222-48–1222. https://doi.org/10.5860/CHOICE.48-1222
Chawla, A., Chawla, R., & Jaggi, S. (2016). Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian Journal of Endocrinology and Metabolism, 20(4), 546–553. https://doi.org/10.4103/2230-8210.183480
Geografi, L., Simbolon, O.M., & Farmasi, I. (2020). Potensi Interaksi Antar Obat Pada Pasien Rawat Inap Diabetes Melitus Tipe-2 Dengan Komorbiditas. 6(1), 129–134
Laakso, M. (2011). Heart in diabetes: A microvascular disease. Diabetes Care, 34(SUPPL. 2), 145–149. https://doi.org/10.2337/dc11-s209
Lee, S.-A., Choi, H.-M., Park, H.-J., Ko, S.-K., & Lee, H.-Y. (2014). Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. The Korean Journal of Internal Medicine, 29(3), 315. https://doi.org/10.3904/kjim.2014.29.3.315
Lehrke, M., & Marx, N. (2017). Diabetes Mellitus and Heart Failure. The American Journal of Cardiology, 120(1S), S37–S47. https://doi.org/10.1016/j.amjcard.2017.05.014
Mauri-Obradors, E., Estrugo-Devesa, A., Jané-Salas, E., Viñas, M., & López-López, J. (2017). Oral manifestations of Diabetes Mellitus. A systematic review. Medicina Oral, Patologia Oral y Cirugia Bucal, 22(5), e586–e594. https://doi.org/10.4317/medoral.21655
May, M., & Schindler, C. (2016). Clinically and pharmacologically relevant interactions of antidiabetic drugs. Therapeutic Advances in Endocrinology and Metabolism, 7(2), 69–83. https://doi.org/10.1177/2042018816638050
Meryta, A., Efrilia, M., & Chandra, P.P.B. (2017). Gambaran Interaksi Obat Hipoglikemik Oral (Oho) Dengan Obat Lain Pada Pasien Diabetes Melitus (Dm) Tipe Ii Di Apotek Imphi Periode Oktober 2014 Sampai Maret 2015. Jurnal Ilmiah Manuntung, 1(2), 193. https://doi.org/10.51352/jim.v1i2.35
Saldanha De Mattos Matheus, A., & Brito Gomes, M. (2013). Early aggressive macrovascular disease and type 1 diabetes mellitus without chronic complications: A case report. BMC Research Notes, 6(1), 1–6. https://doi.org/10.1186/1756-0500-6-222
Simbolon, D., Siregar, A., & Talib, R.A. (2020). Prevention and Control of Type 2 Diabetes Mellitus in Indonesia through the Modification of Physiological Factors and Physical Activities. Kesmas: National Public Health Journal, 15(3), 120–127. https://doi.org/10.21109/kesmas.v15i3.3354
Singh, V.P., Bali, A., Singh, N., & Jaggi, A.S. (2014). Advanced glycation end products and diabetic complications. Korean Journal of Physiology and Pharmacology, 18(1), 1–14. https://doi.org/10.4196/kjpp.2014.18.1.1
Sukmaningsih, V. (2021). Potensi Interaksi Obat Pasien Diabetes Melitus Tipe-2 dengan Hipertensi di Rumah Sakit “ X ” Periode 2019 Period 2019. Sainstech Farma, 14(1), 47–53. https://doi.org/https://doi.org/10.37277/sfj.v14i1.937
Tornio, A., Niemi, M., Neuvonen, P.J., & Backman, J.T. (2012). Drug interactions with oral antidiabetic agents: Pharmacokinetic mechanisms and clinical implications. Trends in Pharmacological Sciences, 33(6), 312–322. https://doi.org/10.1016/j.tips.2012.03.001
Tsimihodimos, V., Gonzalez-Villalpando, C., Meigs, J.B., & Ferrannini, E. (2018). Hypertension and Diabetes Mellitus. Hypertension, 71(3), 422–428. https://doi.org/10.1161/HYPERTENSIONAHA.117.10546
Wong, N.D., Glovaci, D., Wong, K., Malik, S., Franklin, S.S., Wygant, G., & Iloeje, U. (2012). Global cardiovascular disease risk assessment in United States adults with diabetes. Diabetes & Vascular Disease Research, 9(2), 146–152. https://doi.org/10.1177/1479164112436403
